Research programme: obesity therapy - BEXEL Pharmaceuticals

Drug Profile

Research programme: obesity therapy - BEXEL Pharmaceuticals

Alternative Names: BLX-1028; BLX-2002

Latest Information Update: 04 Nov 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator BEXEL Pharmaceuticals
  • Class Amino acids; Dipeptides; Small molecules
  • Mechanism of Action Nitric oxide synthase type II inhibitors; Tumour necrosis factor alpha inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Obesity

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Obesity in USA (PO)
  • 05 Sep 2007 Preclinical development is ongoing
  • 21 Nov 2005 Data presented at the 2005 Annual Meeting of the North American Association for the Study of Obesity (NAASO-2005) have been added to the Obesity pharmacodynamics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top